Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat mesylate for chronic kidney disease patients with COVID-19
ChiCTR2300069312Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Nafabelltan in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Clinical improvement rate. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
Nafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300069312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069312.